These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31159350)

  • 1. Effects of Dapagliflozin on Volume Status When Added to Renin-Angiotensin System Inhibitors.
    Eickhoff MK; Dekkers CCJ; Kramers BJ; Laverman GD; Frimodt-Møller M; Jørgensen NR; Faber J; Danser AHJ; Gansevoort RT; Rossing P; Persson F; Heerspink HJL
    J Clin Med; 2019 May; 8(6):. PubMed ID: 31159350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Adaptive Renal Response for Volume Homeostasis During 2 Weeks of Dapagliflozin Treatment in People With Type 2 Diabetes and Preserved Renal Function on a Sodium-Controlled Diet.
    Scholtes RA; Muskiet MHA; van Baar MJB; Hesp AC; Greasley PJ; Hammarstedt A; Karlsson C; Hallow KM; Danser AHJ; Heerspink HJL; van Raalte DH
    Kidney Int Rep; 2022 May; 7(5):1084-1092. PubMed ID: 35570989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Regulation of natriuresis in diabetic nephropathy].
    Późniak J
    Ann Acad Med Stetin; 2000; 46():241-52. PubMed ID: 11712308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of sodium-glucose cotransporter 2 inhibitor on proximal tubular function and injury in patients with type 2 diabetes: a randomized controlled trial.
    Satirapoj B; Korkiatpitak P; Supasyndh O
    Clin Kidney J; 2019 Jun; 12(3):326-332. PubMed ID: 31198224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes.
    De Nicola L; Gabbai FB; Liberti ME; Sagliocca A; Conte G; Minutolo R
    Am J Kidney Dis; 2014 Jul; 64(1):16-24. PubMed ID: 24673844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose-induced oxidative stress in type 1 diabetic mice.
    Hatanaka T; Ogawa D; Tachibana H; Eguchi J; Inoue T; Yamada H; Takei K; Makino H; Wada J
    Pharmacol Res Perspect; 2016 Aug; 4(4):e00239. PubMed ID: 28116093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the effects of etodolac and ibuprofen on renal haemodynamics, tubular function, renin, vasopressin and urinary excretion of albumin and alpha-glutathione-S-transferase in healthy subjects: a placebo-controlled cross-over study.
    Svendsen KB; Bech JN; Sørensen TB; Pedersen EB
    Eur J Clin Pharmacol; 2000 Aug; 56(5):383-8. PubMed ID: 11009046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis.
    Yavin Y; Mansfield TA; Ptaszynska A; Johnsson K; Parikh S; Johnsson E
    Diabetes Ther; 2016 Mar; 7(1):125-37. PubMed ID: 26758563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dapagliflozin in patients with type 2 diabetes mellitus.
    Filippatos TD; Liberopoulos EN; Elisaf MS
    Ther Adv Endocrinol Metab; 2015 Feb; 6(1):29-41. PubMed ID: 25678954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes.
    Yoshimoto T; Furuki T; Kobori H; Miyakawa M; Imachi H; Murao K; Nishiyama A
    J Investig Med; 2017 Oct; 65(7):1057-1061. PubMed ID: 28596160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the efficacy of SGLT2 inhibitors using semi-mechanistic model.
    Demin O; Yakovleva T; Kolobkov D; Demin O
    Front Pharmacol; 2014; 5():218. PubMed ID: 25352807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes.
    Papakitsou I; Vougiouklakis G; Elisaf MS; Filippatos TD
    Clin Pharmacol; 2019; 11():133-143. PubMed ID: 31572020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus.
    Tanaka H; Takano K; Iijima H; Kubo H; Maruyama N; Hashimoto T; Arakawa K; Togo M; Inagaki N; Kaku K
    Adv Ther; 2017 Feb; 34(2):436-451. PubMed ID: 27981497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents.
    Vivian EM
    Drugs Context; 2014; 3():212264. PubMed ID: 25598831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proximal tubular reabsorption of growth hormone and sodium/fluid in normo- and microalbuminuric insulin-dependent diabetes mellitus.
    Turner G; Coates P; Warren S; Woodhead JS; Peters JR
    Acta Diabetol; 1997 Mar; 34(1):27-32. PubMed ID: 9134054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100,240, on endocrine and renal functions in healthy volunteers.
    Rousso P; Buclin T; Nussberger J; Décosterd LA; La Roche SD; Brunner-Ferber F; Brunner HR; Biollaz J
    J Hypertens; 1999 Mar; 17(3):427-37. PubMed ID: 10100082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.
    Vallon V; Thomson SC
    Diabetologia; 2017 Feb; 60(2):215-225. PubMed ID: 27878313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lithium clearance in the evaluation of segmental renal tubular reabsorption of sodium and water in diabetes mellitus.
    Skøtt P
    Dan Med Bull; 1994 Feb; 41(1):23-37. PubMed ID: 8187564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal and hormonal actions of atrial natriuretic peptide during angiotensin II or noradrenaline infusion in man.
    Eiskjaer H; Nielsen CB; Sørensen SS; Pedersen EB
    Eur J Clin Invest; 1996 Jul; 26(7):584-95. PubMed ID: 8864421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.